臨床試験市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、フェーズ別、試験デザイン別、適応症別、エンドユーザー別、地域別、競合別、2019年～2029年

世界の臨床試験市場は2023年に848億5,000万米ドルと評価され、2029年までCAGR 6.49％で成長すると予測されています。

世界の臨床試験市場は、製薬・ヘルスケア産業における重要な柱として機能しており、新薬、治療法、医療機器が市場に出回る前の評価を促進しています。臨床試験は、治験薬の安全性、有効性、忍容性を評価し、規制当局の承認を導き、臨床診療に情報を提供する上で重要な役割を果たしています。この市場には、製薬企業やバイオテクノロジー企業、CRO（医薬品開発業務受託機関）、学術機関、規制当局、ヘルスケアプロバイダーなど、多様な利害関係者が含まれます。これらの主体は、腫瘍学、循環器疾患から神経学、感染症に至るまで、様々な治療領域にわたる臨床試験の計画、実施、監督を共同で行っています。臨床試験の情勢は、医学、技術、規制状況の進歩に牽引され、絶えず進化しています。精密医療と個別化ヘルスケアの出現により、臨床試験は、特定の治療から最も恩恵を受ける可能性のある患者集団を特定し、それによって治療成果を最適化し、副作用を最小化することにますます焦点が当てられています。臨床研究の世界化は臨床試験の地理的範囲を拡大し、世界中の多様な地域で実施される試験の数が増加しています。この動向は、患者の多様性を高め、未開拓の市場にアクセスし、研究目的のために独自の患者集団を活用しようとする努力を反映しています。革新的な治療法や治療法に対する需要に後押しされ、臨床試験の複雑さと範囲が顕著に拡大しています。バイオ医薬品企業は、アンメットメディカルニーズに対応し、様々な疾患に対する画期的な治療法を開発するために研究開発に多額の投資を行っており、臨床試験市場の拡大に拍車をかけています。臨床試験を取り巻く環境は、コストの上昇、規制状況の厳しさ、患者の確保と維持の問題、倫理的配慮などの課題にも直面しています。これらの課題に対処するには、利害関係者間の協力、革新的な試験デザインと技術の採用、臨床研究の透明性、完全性、患者中心主義の強化に向けた継続的な取り組みが必要です。

市場促進要因

慢性疾患および感染症の有病率の増加

技術の進歩

個別化医療に対する需要の高まり

主な市場課題

患者の確保と維持

データの質と完全性

主な市場動向

治験の分散化とバーチャル化

セグメント別洞察

タイプ別洞察

フェーズ別洞察

地域別洞察

目次

第1章 サービス概要

• 市場の定義
• 市場の範囲
  • 対象市場
  • 調査対象年
  • 主要市場セグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の臨床試験市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別（医薬品臨床試験、医療機器臨床試験）
  • フェーズ別（第i相、第II相、第III相、第IV相）
  • 試験デザイン別（介入、観察、拡大アクセス）
  • 適応症別（自己免疫／炎症、がん、中枢神経系、糖尿病、心血管、その他）
  • エンドユーザー別（臨床研究機関、製薬・バイオテクノロジー企業、臨床試験ラボ、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • タイプ別
  • フェーズ別
  • 試験デザイン別
  • 適応症別
  • エンドユーザー別
  • 地域別

第6章 アジア太平洋の臨床試験市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • フェーズ別
  • 試験デザイン別
  • 適応症別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の臨床試験市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • フェーズ別
  • 試験デザイン別
  • 適応症別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の臨床試験市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • フェーズ別
  • 試験デザイン別
  • 適応症別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の臨床試験市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • フェーズ別
  • 試験デザイン別
  • 適応症別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの臨床試験市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • タイプ別
  • フェーズ別
  • 試験デザイン別
  • 適応症別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• サービスローンチ（もしあれば）
• 合併買収（もしあれば）

第13章 世界の臨床試験市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• SGS SA
• ACM Global Laboratories
• Medpace, Inc.
• ICON plc.
• Charles River Laboratories International, Inc.
• Parexel International（MA）Corporation
• F. Hoffmann-La Roche Ltd
• IQVIA, Inc.
• Syneos Health Inc.
• Thermo Fisher Scientific, Inc.

第16章 戦略的提言

第17章 免責事項

Global Clinical Trials Market was valued at USD 84.85 billion in 2023 and is anticipated to projected to grow with a CAGR of 6.49% through 2029. Global Clinical Trials Market serves as a vital pillar in the pharmaceutical and healthcare industries, facilitating the evaluation of new drugs, treatments, and medical devices before they reach the market. Clinical trials play a crucial role in assessing the safety, efficacy, and tolerability of investigational products, guiding regulatory approvals, and informing clinical practice. The market encompasses a diverse array of stakeholders, including pharmaceutical and biotechnology companies, contract research organizations (CROs), academic institutions, regulatory agencies, and healthcare providers. These entities collaborate to design, conduct, and oversee clinical trials across various therapeutic areas, ranging from oncology and cardiovascular diseases to neurology and infectious diseases. The landscape of clinical trials is continuously evolving, driven by advancements in medical science, technology, and regulatory frameworks. With the emergence of precision medicine and personalized healthcare, clinical trials are increasingly focused on identifying patient subpopulations that may benefit most from specific treatments, thereby optimizing therapeutic outcomes and minimizing adverse effects. The globalization of clinical research has expanded the geographical reach of clinical trials, with a growing number of studies conducted in diverse regions worldwide. This trend reflects efforts to enhance patient diversity, access untapped markets, and leverage unique patient populations for research purposes. There has been a notable increase in the complexity and scope of clinical trials, driven by the demand for innovative therapies and treatments. Biopharmaceutical companies are investing heavily in RD to address unmet medical needs and develop breakthrough treatments for various diseases, fueling the expansion of the clinical trials market. The clinical trials landscape also faces challenges, including rising costs, stringent regulatory requirements, patient recruitment and retention issues, and ethical considerations. Addressing these challenges requires collaboration among stakeholders, adoption of innovative trial designs and technologies, and ongoing efforts to enhance transparency, integrity, and patient-centricity in clinical research.

Key Market Drivers

Increasing Prevalence of Chronic and Infectious Diseases

The increasing prevalence of chronic and infectious diseases significantly impacts the Global Clinical Trials Market, driving the demand for innovative treatments, vaccines, and therapies. Chronic diseases, including cardiovascular diseases, diabetes, cancer, and neurological disorders, are major contributors to global morbidity and mortality rates. As the incidence of these conditions rises worldwide due to factors such as aging populations, lifestyle changes, and urbanization, there is a growing need for clinical trials to develop new therapeutic interventions. The emergence and re-emergence of infectious diseases pose significant public health challenges, exemplified by recent outbreaks such as COVID-19. Infectious diseases can spread rapidly across borders, causing widespread morbidity, mortality, and economic disruption. Clinical trials play a critical role in evaluating the safety and efficacy of vaccines, antiviral drugs, and other interventions to prevent, treat, and control infectious diseases. The increasing prevalence of chronic and infectious diseases underscores the importance of clinical trials as a fundamental component of healthcare research and innovation. These trials provide essential evidence for the development, regulatory approval, and market access of new drugs, devices, and therapies. They contribute to our understanding of disease mechanisms, patient responses to treatment, and factors influencing health outcomes. As the global burden of chronic and infectious diseases continues to grow, the demand for clinical trials is expected to increase correspondingly. This trend highlights the ongoing need for investment in clinical research infrastructure, collaboration among stakeholders, and regulatory support to accelerate the development and delivery of new interventions that address unmet medical needs and improve patient outcomes.

Technological Advancements

Technological advancements play a pivotal role in shaping the landscape of the Global Clinical Trials Market, driving innovation, efficiency, and outcomes across various stages of the clinical research process. These advancements encompass a wide range of technologies, tools, and methodologies that enhance data collection, analysis, monitoring, and patient engagement in clinical trials. The most significant technological advancements in clinical trials is the adoption of electronic data capture (EDC) systems and electronic health records (EHRs). EDC systems streamline data collection and management, enabling real-time access to clinical trial data, improved data quality, and enhanced compliance with regulatory requirements. EHR integration facilitates seamless data exchange between healthcare providers and clinical trial sites, optimizing patient recruitment, eligibility screening, and follow-up. Advancements in mobile health (mHealth) and wearable devices revolutionize patient monitoring and data collection in clinical trials. These technologies enable remote patient monitoring, real-time data tracking, and continuous health monitoring outside traditional clinical settings, enhancing patient engagement, compliance, and safety monitoring. Artificial intelligence (AI) and machine learning (ML) algorithms are increasingly utilized in clinical trials to analyze large datasets, identify patterns, predict patient responses to treatments, and optimize trial design. AI-powered analytics accelerate data analysis, enhance decision-making, and facilitate personalized medicine approaches in clinical research. Virtual and decentralized clinical trials leverage telemedicine platforms, remote monitoring tools, and digital health technologies to conduct trials remotely, reducing patient burden, improving access to diverse patient populations, and accelerating trial timelines. Technological advancements are driving transformative changes in the Global Clinical Trials Market, fostering innovation, efficiency, and patient-centricity in clinical research. As the pace of technological innovation continues to accelerate, stakeholders in the clinical trials ecosystem must adapt and embrace these advancements to unlock new opportunities and address evolving challenges in drug development and healthcare delivery.

Growing Demand for Personalized Medicine

The growing demand for personalized medicine is significantly impacting the Global Clinical Trials Market, driving a shift towards more targeted and individualized approaches to healthcare. Personalized medicine, also known as precision medicine, involves tailoring medical treatments and interventions to the specific characteristics of each patient, including their genetic makeup, molecular profiles, and environmental factors. This approach aims to maximize treatment efficacy, minimize adverse effects, and optimize patient outcomes. Clinical trials play a crucial role in advancing personalized medicine by evaluating the safety, efficacy, and predictive value of biomarkers, companion diagnostics, and targeted therapies. These trials aim to identify patient subpopulations that are most likely to benefit from specific treatments, enabling more precise and effective therapeutic interventions. The demand for personalized medicine is driven by several factors, including advances in genomics, molecular diagnostics, and bioinformatics, which have enabled the identification of biomarkers and therapeutic targets associated with various diseases. The increasing availability of high-throughput sequencing technologies and 'omics' data has facilitated the discovery of genetic mutations, gene expression patterns, and molecular signatures that inform personalized treatment strategies. The rising prevalence of complex and heterogeneous diseases, such as cancer, cardiovascular diseases, and neurological disorders, underscores the need for personalized approaches to diagnosis and treatment. Clinical trials focused on personalized medicine offer opportunities to validate biomarkers, validate predictive models, and assess the efficacy of targeted therapies in specific patient populations. The growing demand for personalized medicine is driving increased investment in clinical trials that support the development and validation of personalized treatment approaches. These trials hold promise for improving patient outcomes, reducing healthcare costs, and advancing precision medicine as a cornerstone of modern healthcare delivery.

Key Market Challenges

Patient Recruitment and Retention

Patient recruitment and retention are critical challenges in the Global Clinical Trials Market, significantly impacting trial timelines, costs, and the overall success of research endeavors. Effective recruitment strategies are essential for enrolling a diverse and representative patient population, while retention efforts aim to ensure participant compliance, engagement, and completion of the trial protocol. Recruiting eligible participants for clinical trials is often challenging due to various factors. One key challenge is the strict eligibility criteria imposed by study protocols, which may exclude many potential candidates.The limited patient awareness about clinical trials, misconceptions about research participation, and reluctance to deviate from standard treatment options pose barriers to recruitment efforts. Furthermore, competition for eligible participants among multiple trials, particularly in rare disease indications or niche populations, exacerbates recruitment challenges. The retaining participants throughout the duration of the trial presents another set of obstacles. Patient attrition can occur due to factors such as adverse events, treatment dissatisfaction, protocol non-compliance, or loss to follow-up. Maintaining participant engagement, adherence to study procedures, and ongoing communication with trial sites are crucial for mitigating attrition risks. To address patient recruitment and retention challenges, sponsors and investigators employ various strategies. These may include targeted outreach and education campaigns to raise awareness about clinical trials, community engagement initiatives to build trust and rapport, and the implementation of patient-centric trial designs that prioritize participant needs and preferences. Leveraging digital technologies, such as patient registries, social media platforms, and telemedicine, can enhance recruitment efficiency and facilitate remote monitoring to improve retention rates. The overcoming patient recruitment and retention challenges requires innovative approaches, collaborative efforts among stakeholders, and a patient-centered approach to clinical trial design and implementation. By addressing these challenges, the Global Clinical Trials Market can optimize patient enrollment, enhance trial efficiency, and accelerate the development of new therapies and treatments.

Data Quality and Integrity

Data quality and integrity are paramount considerations in the Global Clinical Trials Market, as they directly impact the reliability, validity, and credibility of trial results. Ensuring high-quality data is essential for generating robust evidence to support regulatory submissions, inform clinical decision-making, and advance medical knowledge. The primary challenges in maintaining data quality and integrity is the potential for data discrepancies, errors, and inaccuracies. These can arise from various sources, including human error, protocol deviations, transcription mistakes, or inadequate documentation practices. Addressing these challenges requires implementing rigorous data management protocols, standardized data collection procedures, and comprehensive training for trial personnel. Maintaining data integrity involves safeguarding against data fraud, manipulation, or misconduct, which can compromise the integrity of trial results and undermine patient safety. Regulatory agencies and ethics committees impose strict guidelines and oversight mechanisms to ensure compliance with ethical standards, data protection regulations, and Good Clinical Practice (GCP) guidelines. Technological advancements, such as electronic data capture (EDC) systems, electronic health records (EHRs), and blockchain technology, offer opportunities to enhance data quality and integrity in clinical trials. EDC systems enable real-time data collection, validation, and monitoring, reducing the risk of data entry errors and improving data accuracy. Blockchain technology provides secure, immutable data storage, ensuring transparency, traceability, and tamper-proof data integrity. The comprehensive data monitoring and quality assurance processes, including source data verification, query resolution, and statistical analysis, are integral to maintaining data quality throughout the trial lifecycle. Independent data monitoring committees (DMCs) and clinical research organizations (CROs) play essential roles in overseeing data integrity and compliance with regulatory requirements.

Key Market Trends

Decentralized and Virtual Trials

Decentralized and virtual trials represent a transformative trend in the Global Clinical Trials Market, revolutionizing the way clinical research is conducted and patient participation is facilitated. These trial models leverage digital technologies, telemedicine platforms, and remote monitoring tools to enable patients to participate in trials from their homes or local healthcare facilities, eliminating the need for frequent in-person visits to traditional clinical trial sites. The key advantages of decentralized and virtual trials is improved patient access and participation. By removing geographical barriers and reducing logistical burdens associated with travel to trial sites, these models expand the pool of eligible participants and enhance diversity in trial populations. This inclusivity facilitates recruitment efforts, accelerates patient enrollment, and enables more representative study results. Decentralized and virtual trials offer benefits in terms of patient convenience, comfort, and flexibility. Participants have greater autonomy over their involvement in the trial, allowing them to schedule visits at their convenience, reduce disruptions to their daily lives, and minimize the burden of travel and time commitments. This enhanced patient experience promotes higher engagement, adherence to study protocols, and retention rates throughout the trial duration. Decentralized and virtual trial models promote operational efficiencies and cost savings for trial sponsors and investigators. By leveraging digital platforms for data collection, monitoring, and communication, these models streamline trial workflows, reduce administrative burdens, and optimize resource allocation. Virtual trial models enable real-time data monitoring and analysis, facilitating rapid decision-making, adaptive trial designs, and efficient protocol amendments.

Segmental Insights

Type Insights

Based ontype,Pharmaceutical Trials segment dominated the Global Clinical Trials Market in 2023.This is due to the extensive research and development activities in the pharmaceutical industry, driven by the continuous demand for novel drugs and therapeutics. Pharmaceutical trials often involve testing the safety and efficacy of new drugs or treatments for various diseases and medical conditions, which requires a significant portion of the clinical trial budget. The regulatory approvals and market access for pharmaceutical products heavily rely on the outcomes of these trials, further emphasizing their prominence in the global clinical trials landscape.

Phase Insights

Based on phase, Phase III segment dominated the Global Clinical Trials Market in 2023. Phase III trials are pivotal in determining the safety and efficacy of investigational drugs or treatments before regulatory approval. These trials involve large-scale testing on diverse patient populations, providing robust evidence for regulatory submissions and market authorization. The substantial investment and resources allocated to Phase III trials, along with their critical role in the drug development process, contribute to their dominance in the global clinical trials landscape. The successful Phase III trials are often prerequisite for commercialization, further highlighting their significance.

Regional Insights

North America is dominated the Global Clinical Trials Market in 2023. This is because the region's unparalleled commitment to research and development (RD). The United States in particular is renowned for its robust healthcare infrastructure, world-class research institutions, and extensive funding for biomedical research, making it a global leader in clinical trials. The region boasts a vast network of pharmaceutical and biotechnology companies, academic institutions, and government agencies that allocate substantial resources towards developing new drugs, therapies, and medical devices. These organizations conduct a considerable number of clinical trials across various therapeutic areas, contributing to North America's prominence in the global clinical trials market.

Key Market Players

SGS SA

ACM Global Laboratories

Medpace, Inc.

ICON plc.

Charles River Laboratories International, Inc.

Parexel International (MA) Corporation

F. Hoffmann-La Roche Ltd

IQVIA, Inc.

Syneos Health Inc.

Thermo Fisher Scientific, Inc.

Report Scope:

In this report, the Global Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trials Market,By Drug Type:

• Pharmaceutical Trials
• Medical Device Trials

Clinical Trials Market,By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

Clinical Trials Market,By Study Design:

• Interventional
• Observational
• Expanded Access

Clinical Trials Market,ByIndication:

• Autoimmune/Inflammation
• Oncology
• CNS
• Diabetes
• Cardiovascular
• Others

Clinical Trials Market,By End User:

• Clinical Research Organizations
• Pharmaceutical and Biotechnological Companies
• Clinical Testing Laboratories
• Others

Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Clinical Trials Market.

Available Customizations:

Global Clinical Trials Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Service Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Clinical Trials Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Type (Pharmaceutical Trials, Medical Device Trials)
  • 5.2.2.By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.3.By Study Design (Interventional, Observational, Expanded Access)
  • 5.2.4.By Indication (Autoimmune/Inflammation, Oncology, CNS, Diabetes, Cardiovascular, Others)
  • 5.2.5.By End User (Clinical Research Organizations, Pharmaceutical and Biotechnological Companies, Clinical Testing Laboratories, Others)
  • 5.2.6.By Region
  • 5.2.7.By Company (2023)
• 5.3.Market Map
  • 5.3.1.By Type
  • 5.3.2.By Phase
  • 5.3.3.By Study Design
  • 5.3.4.By Indication
  • 5.3.5.By End User
  • 5.3.6.By Region

6.Asia Pacific Clinical Trials Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Type
  • 6.2.2.By Phase
  • 6.2.3.By Study Design
  • 6.2.4.By Indication
  • 6.2.5.By End User
  • 6.2.6.By Country
• 6.3.Asia Pacific: Country Analysis
  • 6.3.1.China Clinical Trials Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Type
      • 6.3.1.2.2.By Phase
      • 6.3.1.2.3.By Study Design
      • 6.3.1.2.4.By Indication
      • 6.3.1.2.5.By End User
  • 6.3.2.India Clinical Trials Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Type
      • 6.3.2.2.2.By Phase
      • 6.3.2.2.3.By Study Design
      • 6.3.2.2.4.By Indication
      • 6.3.2.2.5.By End User
  • 6.3.3.Australia Clinical Trials Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Type
      • 6.3.3.2.2.By Phase
      • 6.3.3.2.3.By Study Design
      • 6.3.3.2.4.By Indication
      • 6.3.3.2.5.By End User
  • 6.3.4.Japan Clinical Trials Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Type
      • 6.3.4.2.2.By Phase
      • 6.3.4.2.3.By Study Design
      • 6.3.4.2.4.By Indication
      • 6.3.4.2.5.By End User
  • 6.3.5.South Korea Clinical Trials Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Type
      • 6.3.5.2.2.By Phase
      • 6.3.5.2.3.By Study Design
      • 6.3.5.2.4.By Indication
      • 6.3.5.2.5.By End User

7.Europe Clinical Trials Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Type
  • 7.2.2.By Phase
  • 7.2.3.By Study Design
  • 7.2.4.By Indication
  • 7.2.5.By End User
  • 7.2.6.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.France Clinical Trials Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Type
      • 7.3.1.2.2.By Phase
      • 7.3.1.2.3.By Study Design
      • 7.3.1.2.4.By Indication
      • 7.3.1.2.5.By End User
  • 7.3.2.Germany Clinical Trials Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Type
      • 7.3.2.2.2.By Phase
      • 7.3.2.2.3.By Study Design
      • 7.3.2.2.4.By Indication
      • 7.3.2.2.5.By End User
  • 7.3.3.Spain Clinical Trials Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Type
      • 7.3.3.2.2.By Phase
      • 7.3.3.2.3.By Study Design
      • 7.3.3.2.4.By Indication
      • 7.3.3.2.5.By End User
  • 7.3.4.Italy Clinical Trials Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Type
      • 7.3.4.2.2.By Phase
      • 7.3.4.2.3.By Study Design
      • 7.3.4.2.4.By Indication
      • 7.3.4.2.5.By End User
  • 7.3.5.United Kingdom Clinical Trials Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Type
      • 7.3.5.2.2.By Phase
      • 7.3.5.2.3.By Study Design
      • 7.3.5.2.4.By Indication
      • 7.3.5.2.5.By End User

8.North America Clinical Trials Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Type
  • 8.2.2.By Phase
  • 8.2.3.By Study Design
  • 8.2.4.By Indication
  • 8.2.5.By End User
  • 8.2.6.By Country
• 8.3.North America: Country Analysis
  • 8.3.1.United States Clinical Trials Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Type
      • 8.3.1.2.2.By Phase
      • 8.3.1.2.3.By Study Design
      • 8.3.1.2.4.By Indication
      • 8.3.1.2.5.By End User
  • 8.3.2.Mexico Clinical Trials Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Type
      • 8.3.2.2.2.By Phase
      • 8.3.2.2.3.By Study Design
      • 8.3.2.2.4.By Indication
      • 8.3.2.2.5.By End User
  • 8.3.3.Canada Clinical Trials Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Type
      • 8.3.3.2.2.By Phase
      • 8.3.3.2.3.By Study Design
      • 8.3.3.2.4.By Indication
      • 8.3.3.2.5.By End User

9.South America Clinical Trials Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Type
  • 9.2.2.By Phase
  • 9.2.3.By Study Design
  • 9.2.4.By Indication
  • 9.2.5.By End User
  • 9.2.6.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Clinical Trials Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Type
      • 9.3.1.2.2.By Phase
      • 9.3.1.2.3.By Study Design
      • 9.3.1.2.4.By Indication
      • 9.3.1.2.5.By End User
  • 9.3.2.Argentina Clinical Trials Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Type
      • 9.3.2.2.2.By Phase
      • 9.3.2.2.3.By Study Design
      • 9.3.2.2.4.By Indication
      • 9.3.2.2.5.By End User
  • 9.3.3.Colombia Clinical Trials Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Type
      • 9.3.3.2.2.By Phase
      • 9.3.3.2.3.By Study Design
      • 9.3.3.2.4.By Indication
      • 9.3.3.2.5.By End User

10.Middle East and Africa Clinical Trials Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Type
  • 10.2.2.By Phase
  • 10.2.3.By Study Design
  • 10.2.4.By Indication
  • 10.2.5.By End User
  • 10.2.6.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Clinical Trials Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Type
      • 10.3.1.2.2.By Phase
      • 10.3.1.2.3.By Study Design
      • 10.3.1.2.4.By Indication
      • 10.3.1.2.5.By End User
  • 10.3.2.Saudi Arabia Clinical Trials Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Type
      • 10.3.2.2.2.By Phase
      • 10.3.2.2.3.By Study Design
      • 10.3.2.2.4.By Indication
      • 10.3.2.2.5.By End User
  • 10.3.3.UAE Clinical Trials Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Type
      • 10.3.3.2.2.By Phase
      • 10.3.3.2.3.By Study Design
      • 10.3.3.2.4.By Indication
      • 10.3.3.2.5.By End User
  • 10.3.4.Egypt Clinical Trials Market Outlook
    • 10.3.4.1.Market Size Forecast
      • 10.3.4.1.1.By Value
    • 10.3.4.2.Market Share Forecast
      • 10.3.4.2.1.By Type
      • 10.3.4.2.2.By Phase
      • 10.3.4.2.3.By Study Design
      • 10.3.4.2.4.By Indication
      • 10.3.4.2.5.By End User

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Recent Developments
• 12.2.Service Launches (If Any)
• 12.3.Mergers Acquisitions (If Any)

13.Global Clinical Trials Market: SWOT Analysis

14.Porter's Five Forces Analysis

• 14.1.Competition in the Industry
• 14.2.Potential of New Entrants
• 14.3.Power of Suppliers
• 14.4.Power of Customers
• 14.5.Threat of Substitute Services

15.Competitive Landscape

• 15.1.SGS SA
  • 15.1.1.Business Overview
  • 15.1.2.Company Snapshot
  • 15.1.3.Products Services
  • 15.1.4.Financials (In case of listed)
  • 15.1.5.Recent Developments
  • 15.1.6.SWOT Analysis
• 15.2.ACM Global Laboratories
• 15.3.Medpace, Inc.
• 15.4.ICON plc.
• 15.5.Charles River Laboratories International, Inc.
• 15.6.Parexel International (MA) Corporation
• 15.7.F. Hoffmann-La Roche Ltd
• 15.8.IQVIA, Inc.
• 15.9.Syneos Health Inc.
• 15.10.Thermo Fisher Scientific, Inc.

16.Strategic Recommendations

17. About Us Disclaimer